IBDEI1G6 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23412,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,23412,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,23413,0)
 ;;=Z79.01^^78^1009^14
 ;;^UTILITY(U,$J,358.3,23413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23413,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,23413,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,23413,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,23414,0)
 ;;=Z79.02^^78^1009^15
 ;;^UTILITY(U,$J,358.3,23414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23414,1,3,0)
 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,23414,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,23414,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,23415,0)
 ;;=D68.62^^78^1009^16
 ;;^UTILITY(U,$J,358.3,23415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23415,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,23415,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,23415,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,23416,0)
 ;;=I73.9^^78^1009^17
 ;;^UTILITY(U,$J,358.3,23416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23416,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,23416,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,23416,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,23417,0)
 ;;=Z86.79^^78^1009^18
 ;;^UTILITY(U,$J,358.3,23417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23417,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,23417,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,23417,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,23418,0)
 ;;=Z86.711^^78^1009^19
 ;;^UTILITY(U,$J,358.3,23418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23418,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,23418,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,23418,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,23419,0)
 ;;=Z86.718^^78^1009^20
 ;;^UTILITY(U,$J,358.3,23419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23419,1,3,0)
 ;;=3^Personal Hx of Venous Thrombosis/Embolism
 ;;^UTILITY(U,$J,358.3,23419,1,4,0)
 ;;=4^Z86.718
 ;;^UTILITY(U,$J,358.3,23419,2)
 ;;=^5063475
 ;;^UTILITY(U,$J,358.3,23420,0)
 ;;=Z95.2^^78^1009^21
 ;;^UTILITY(U,$J,358.3,23420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23420,1,3,0)
 ;;=3^Presence of Prosthetic Heart Valve
 ;;^UTILITY(U,$J,358.3,23420,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,23420,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,23421,0)
 ;;=D68.59^^78^1009^22
 ;;^UTILITY(U,$J,358.3,23421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23421,1,3,0)
 ;;=3^Primary Thrombophilia
 ;;^UTILITY(U,$J,358.3,23421,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,23421,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,23422,0)
 ;;=I26.99^^78^1009^23
 ;;^UTILITY(U,$J,358.3,23422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23422,1,3,0)
 ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
 ;;^UTILITY(U,$J,358.3,23422,1,4,0)
 ;;=4^I26.99
 ;;^UTILITY(U,$J,358.3,23422,2)
 ;;=^5007150
 ;;^UTILITY(U,$J,358.3,23423,0)
 ;;=I42.5^^78^1009^24
 ;;^UTILITY(U,$J,358.3,23423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23423,1,3,0)
 ;;=3^Restrictive Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,23423,1,4,0)
 ;;=4^I42.5
 ;;^UTILITY(U,$J,358.3,23423,2)
 ;;=^5007196
 ;;^UTILITY(U,$J,358.3,23424,0)
 ;;=G45.9^^78^1009^26
 ;;^UTILITY(U,$J,358.3,23424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23424,1,3,0)
 ;;=3^Transient Cerebral Ischemic Attack,Unspec
 ;;^UTILITY(U,$J,358.3,23424,1,4,0)
 ;;=4^G45.9
